Common (>10%, often universal):

• Cheilitis (lip dryness, peeling, cracking) — 90%+ of users. Manage with constant lip emollient (Aquaphor, Vaseline, Burt's Bees) applied 5-15× per day.
• Xerosis (dry skin) — 70-90% of users. Manage with bland fragrance-free moisturizers, gentle cleansers.
• Dry eyes / blepharitis — 30-50% of users. Manage with preservative-free artificial tears, avoid contact lens wear during course if possible.
• Dry nasal mucosa, epistaxis — 30-60% of users. Manage with saline nasal spray, petroleum jelly inside nostril. Athlete-relevant: training + dry nose = nosebleeds.
• Photosensitivity — 50%+ of users. Daily SPF 30+ mandatory.
• Elevated triglycerides — 25-45% of users (mild-moderate elevations)
• Elevated LFTs (ALT, AST) — 5-15% of users (mild-moderate)
• Arthralgia, myalgia, back pain — 15-35% of users. Combat-sport relevant.
• Hair thinning — 10-30% of users (typically reverses post-treatment; rarely permanent)

Less common (1-10%):

• Headache (mild-moderate) — 5-10%
• Mood changes, depression, irritability — see neuropsychiatric section below; rate disputed; signal real
• Conjunctivitis, decreased night vision — 3-8%
• Hyperostoses, premature epiphyseal closure (in adolescents on chronic high-dose) — uncommon at standard course
• Hair texture changes, hair loss — 5-15%
• Skin fragility, secondary infection of dry/cracked areas — variable
• GI: nausea, abdominal pain — 5-10%
• Sweating changes, altered thermoregulation — anecdotal

Rare-serious (<1%, but worth knowing):

• Severe hypertriglyceridemia → pancreatitis — <1% but catastrophic. Monitor lipids; if TG > 500 mg/dL, dose reduce or discontinue.
• Severe hepatotoxicity — <1%; usually reversible with discontinuation
• Pseudotumor cerebri (idiopathic intracranial hypertension) — rare. Massively increased risk if combined with tetracyclines (concurrent doxycycline + isotretinoin contraindicated). Symptoms: headache, papilledema, visual changes, vomiting. Stop drug immediately.
• Inflammatory bowel disease (causal link debated 2010s; more recent evidence reassuring). Multiple case reports + cohort studies in 2010-2014 raised concern for IBD trigger. Subsequent larger analyses (e.g., Crockett et al. 2010; Etminan et al. 2013; meta-analyses through 2024) have been more reassuring — most show no significant increased IBD risk after controlling for acne severity (severe acne itself associates with IBD independently). Current dermatology consensus: low if any causal contribution, but caution in patients with personal or strong family history of IBD.
• DISH (diffuse idiopathic skeletal hyperostosis), premature epiphyseal closure — chronic high-dose long-term use; rare at standard 4-6 month courses
• Stevens-Johnson syndrome, toxic epidermal necrolysis — rare hypersensitivity reactions
• Allergic interstitial nephritis, glomerulonephritis — rare
• Severe depression / suicidality — see neuropsychiatric section

The neuropsychiatric question (the depression black box):

• The black box warning has been on isotretinoin since the late 1990s, mandating physician + patient awareness of depression, psychosis, suicidal ideation, and suicide as potential adverse events.
• The epidemiologic evidence is mixed. Some large cohort studies (Sundström et al. 2010 BMJ; Bremner et al. 2012) found relative risk 1.3-1.5 for depression / suicidal ideation in isotretinoin users vs. comparison populations. Other studies (Marqueling + Zane 2007 review; Strahan + Raimer 2006) found no significant increase or even improvement (because clearing severe acne reduces depressive burden).
• The 2024 Cochrane review and recent meta-analyses (Huang + Cheng 2017; Bremner 2021; subsequent updates through early 2026) have been more reassuring at the population level — finding no convincing evidence of increased depression risk when comparing isotretinoin users to acne patients on alternative treatments, and noting that acne severity itself is the strongest predictor of depression in the population, with isotretinoin treatment generally improving mood by clearing the underlying skin disease.
• However, the case-report and individual-user signal is real. A subset of users — likely with underlying genetic or pre-existing psychiatric vulnerability — develop new-onset or worsened depression, sometimes with sudden onset, sometimes resolving with discontinuation, sometimes persistent. No reliable predictor. Personal or family history of depression, anxiety, or other psychiatric conditions is the strongest signal to take seriously.
• Mechanism (speculative): Retinoid receptors are expressed in CNS; chronic high-dose retinoid signaling in animal models alters serotonin signaling, hippocampal neurogenesis, HPA-axis function, and prefrontal cortex activity. Some evidence of altered amygdala reactivity in functional MRI studies of isotretinoin users.
• For the user's brain-priority profile: This is the single most important non-MMA reason to keep isotretinoin SKIP-FOR-NOW. A 20yo on a heavy nootropic stack, with brain priority, doing daily cognitive self-monitoring — adding a drug with a real-but-contested mood signal is exactly the wrong addition unless the indication forces the issue. POD doesn't force it.
• If the user ever does take isotretinoin (for severe nodulocystic acne or truly recalcitrant POD): mandatory monthly PHQ-9 / depression screening, immediate discontinuation if any mood symptom emerges, dermatologist who takes the mood-monitoring seriously rather than dismissing it.

Specific watch periods:

• First 4 weeks: lip cheilitis onset, initial acne purge, baseline lab follow-up at week 4
• Weeks 4-8: lipid panel + LFTs at 4-week intervals
• Weeks 8-12: peak side-effect burden typically; arthralgia onset commonly here
• Continuous: any mood change, suicidal ideation, severe headache (pseudotumor), severe abdominal pain (pancreatitis), any visual symptoms